Forma Therapeutics (FMTX) Downgraded by Zacks Investment Research to Sell

Forma Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Forma Therapeutics Downgraded by Zacks Investment Research on 10/11/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of Forma Therapeutics traded down -$0.31 on Monday, reaching $18.42. 285560 shares of the stock traded hands, compared to its average volume of 351781. Shares of Forma Therapeutics were trading at $18.42 on Monday. The firm’s 50 day moving average is $23.14 and its 200 day moving average is $28.73.Forma Therapeutics has a 12 month low of $17.92 and a 12 month high of $56.33. While on yearly highs and lows, Forma Therapeutics’s today has traded high as $18.93 and has touched $17.92 on the downward trend. See More Analyst Rating at: RATING

Forma Therapeutics Earnings and What to expect: 

Forma Therapeutics last announced its quarterly earnings results on August 12th, 2021. The reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by $0.13. Forma Therapeutics has generated ($3.22) earnings per share over the last year (($3.03) diluted earnings per share). Earnings for Forma Therapeutics are expected to decrease in the coming year, from ($3.35) to ($4.02) per share. Forma Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

Earnings for Forma Therapeutics are expected to decrease in the coming year, from ($3.35) to ($4.02) per share. The P/E ratio of Forma Therapeutics is -6.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Forma Therapeutics is -6.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Forma Therapeutics has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Forma Therapeutics (FMTX) Moving Average Technical Analysis

5 day Moving Average is $21.20 And 5 day price change is -$5.68 (-23.57%)  with average volume for 5 day average is 322,360. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $22.86 and 20 day price change is -$3.83 (-17.21%) and average 20 day moving volume is 427,200. 50 day moving average is $23.14  and 50 day price change is -$4.47 ( -19.53%)  and with average volume for 50 days is : 309,150. 200 day moving average is $28.73  and 200 day price change is -$20.93 (-53.19%)  and with average volume for 200 days is : 377,310.

Other owners latest trading in Forma Therapeutics :

  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 91,487 which equates to market value of $2.28M and appx 0.00% owners of Forma Therapeutics
  • On 8/30/2021 shares held by Integral Health Asset Management LLC were 45,000 which equates to market value of $1.12M and appx 0.30% owners of Forma Therapeutics
  • On 8/23/2021 shares held by Morgan Stanley were 108,462 which equates to market value of $2.70M and appx 0.00% owners of Forma Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 85.18% for Forma Therapeutics

See More Analyst Rating at: RATING